Quantcast

Latest adjuvant therapy Stories

2014-04-04 23:36:36

Active research in breast cancer is producing novel targeted drugs at a rapid pace. Thousand Oaks, California (PRWEB) April 03, 2014 As the Cancer society continues research for breast cancer, several options have emerged. Of these options three drugs have been approved by the FDA for usage as treatment and no one is more excited than Dr. Mai Brooks. Perjeta (pertuzumab) In September 2013, the FDA approved Perjeta for use in combination with Herceptin (trastuzumab) and docetaxel for the...

2014-04-01 13:06:26

Bottom Line: Taking low doses of aspirin (which inhibits platelet function) after a colon cancer diagnosis appears to be associated with better survival if the tumor cells express HLA class I antigen. Author: Marlies S. Reimers, M.D., Leiden University Medical Center, the Netherlands, and colleagues. Background: Prior research has suggested aspirin use after a colorectal cancer diagnosis might improve survival. Although the precise mechanism of aspirin's anti-cancer effect is unknown,...

2014-03-31 10:00:45

Physicians have long suspected that chemotherapy can accelerate the aging process in patients treated for cancer. Using a test developed at UNC Lineberger Comprehensive Cancer Center to determine molecular aging, UNC oncologists have directly measured the impact of anti-cancer chemotherapy drugs on biological aging. Researchers measured the level of p16, a protein that causes cellular aging, in the blood of 33 women over the age of 50 who had undergone chemotherapy for curable breast...

2014-03-19 08:29:07

Data Presented at 9th European Breast Cancer (EBCC-9) Symposium Highlights Comprehensive Body of Clinical Evidence for Oncotype DX REDWOOD CITY, Calif., March 19, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of multiple Oncotype DX® breast cancer studies at the 9(th) European Breast Cancer Conference (EBCC-9), which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that...

2014-01-15 08:28:21

Trial Will Compare Investigational Compound's Efficacy and Safety as an Addition to Standard Treatment NORTH CHICAGO, Ill., Jan. 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888) when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer. The three-arm trial will compare the addition of veliparib plus...

2013-12-13 23:01:59

An analysis by ECOG-ACRIN researchers shows that TILs are a prognostic factor in women with triple negative breast cancer. San Antonio, TX (PRWEB) December 13, 2013 An analysis presented by researchers from the ECOG-ACRIN Cancer Research Group this week at the San Antonio Breast Cancer Symposium showed that stromal tumor-infiltrating lymphocytes (TILs) represent a robust prognostic factor in patients with triple-negative breast cancer (TNBC) who are treated with standard adjuvant...

2013-12-11 12:07:24

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. "Worldwide, anthracyclines such as doxorubicin [Adriamycin] and epirubicin have...

2013-12-11 12:02:49

Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10–14. "NeoALTTO is a randomized, phase III clinical trial evaluating whether a combination of two HER2-targeted therapies, trastuzumab and lapatinib, given with standard paclitaxel chemotherapy before...

2013-11-06 13:45:35

Long term results of the randomized phase III EORTC intergroup trial 40983 were recently reported in The Lancet Oncology. The observed 4.1% difference in overall survival at five years for patients with initially resectable liver metastases from colorectal cancer was not significant for perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) compared with surgery alone. Earlier results of this same trial had shown that perioperative chemotherapy with FOLFOX4...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related